Assignee
HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH
DE·22 granted patents·22 pending applications·10 citations·filing 2008–2023
Top patents by PatentIndex Score
44 records- 0175US10383950B2Methods and compositions of carrier systems for the purpose of intracellular drug targetingHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2015·Granted Aug 20, 2019·4 cites·27 claims
- 0275US10188682B2Medicament for liver regeneration and for treatment of liver failureHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2015·Granted Jan 29, 2019·2 cites·4 claims
- 0372US11883387B2PqsR inverse agonistsHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2019·Granted Jan 30, 2024·2 cites·17 claims
- 0468US10793600B2CystobactamidesHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2018·Granted Oct 6, 2020·1 cites·7 claims
- 0567US11975032B2Medicament for liver regeneration and for treatment of liver failureHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2018·Granted May 7, 2024·0 cites·8 claims
- 0661US10519099B2CystobactamidesHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2015·Granted Dec 31, 2019·1 cites·17 claims
- 0760US10905761B2Use of a lipopeptide or lipoprotein as an adjuvant in therapeutic or prophylactic vaccinationsHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2013·Granted Feb 2, 2021·0 cites·11 claims
- 0860US2025092421A1A murine cytomegalovirus vaccine vector for administration in a non-mouse subjectHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2023·Application pending·0 cites
- 0959US2023260597A1Method for prediction of the guide efficiency when targeting a gene of interestHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2021·Application pending·0 cites
- 1058US2024041950A1Decolonization of enterobacteria, such as klebsiella pneumoniae, from the gut using strains of klebsiella oxytocaHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2021·Application pending·0 cites
- 1157US11225503B2CrystobactamidesHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2020·Granted Jan 18, 2022·0 cites·5 claims
- 1255US2025170104A1INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR LasßHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2023·Application pending·0 cites
- 1355US2023175078A1Rna detection and transcription-dependent editing with reprogrammed tracrrnasHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2021·Application pending·0 cites
- 1455US2025276998A1Novel darobactin derivativesHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2022·Application pending·0 cites
- 1554US2024368065A1Citraconic acid and derivatives thereof for use as a medicamentHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2022·Application pending·0 cites
- 1650US2023179656A1Method for synchronising data of a database, computer programme, device for processing data, and mobile terminal thereforHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2021·Application pending·0 cites
- 1750US2022257752A1New use of cyclic dinucleotidesHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2020·Application pending·0 cites
- 1849US11331371B2Labyrinthopeptins as anti-viral agentsHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2019·Granted May 17, 2022·0 cites·13 claims
- 1949US2023285590A1Polymer-cargo-complexes comprising cross-linked copolymers and cargo moleculesHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2021·Application pending·0 cites
- 2049US2024376084A1Inhibitors of alpha-hemolysin of staphylococcus aureusHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2022·Application pending·0 cites
- 2147US11839658B2Aminoglycoside derivatives and nano-assemblies thereof, including those with quorum sensing inhibitory functionHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2018·Granted Dec 12, 2023·0 cites·15 claims
- 2246US2023321123A1INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR LasBHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2021·Application pending·0 cites
- 2344US2025295790A1Lectin-targeting conjugatesHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2022·Application pending·0 cites
- 2442US2020392071A1Gene cluster for the biosynthetic production of tetracycline compounds in a heterologous hostHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2018·Application pending·0 cites
- 2541US12528783B2PqsR inverse agonistsHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2020·Granted Jan 20, 2026·0 cites·15 claims
- 2641US11236135B2Salmonella and immunogenic composition containing the same as well as its useHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2018·Granted Feb 1, 2022·0 cites·14 claims
- 2741US2019046604A1Labyrinthopeptins as anti-viral agentsHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2016·Application pending·0 cites
- 2840US12564631B2Phytosphingosine derivatives as adjuvants in immune stimulationHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2021·Granted Mar 3, 2026·0 cites·20 claims
- 2940US2023146507A1N-phenyl-3-mercaptopropanamide derivatives as metallo-beta-lactamase inhibitors for the treatment of bacterial infectionsHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2021·Application pending·0 cites
- 3039US11357752B2Carolacton and derivatives thereof for use in the treatment of cell proliferation disordersHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2018·Granted Jun 14, 2022·0 cites·9 claims
- 3139US11236059B2Targeted cytotoxic ratjadone derivatives and conjugates thereofHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2018·Granted Feb 1, 2022·0 cites·16 claims
- 3238US2023106506A1NOVEL PqsR INVERSE AGONISTSHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2020·Application pending·0 cites
- 3337US12545699B2Bivalent LECA inhibitors targeting biofilm formation of Pseudomonas aeruginosaHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2020·Granted Feb 10, 2026·0 cites·11 claims
- 3437US10520488B2Method and measuring device for determination of the growth rate of biofilmHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2015·Granted Dec 31, 2019·0 cites·6 claims
- 3537US2021030865A1Method for determining vaccine efficacy in an individual and means thereforeHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2019·Application pending·0 cites
- 3637US2011064769A1Vv promoter-driven overexpression of recombinant antigensHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2008·Application pending·0 cites
- 3735US10472326B2PQSR modulatorsHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2014·Granted Nov 12, 2019·0 cites·9 claims
- 3831US11365201B2Chlorotonil derivativesHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2018·Granted Jun 21, 2022·0 cites·17 claims
- 3931US2015203878A1Pha-producing genetically engineered microorganismsHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2013·Application pending·0 cites
- 4027US11034648B2Cystobactamide derivativesHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2018·Granted Jun 15, 2021·0 cites·19 claims
- 4127US2019345542A1Rapid antimicrobial susceptibility testing and phylogenetic identificationHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2018·Application pending·0 cites
- 4227US2020231562A1Novel macrolide antibioticsHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2015·Application pending·0 cites
- 4320US11072590B21,4,7,10-tetrazacyclododecane based agents to target bacteria and its useHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2015·Granted Jul 27, 2021·0 cites·12 claims
- 4420US10407398B2Inhibitors of Pseudomonas aeruginosa LecBHELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH·Filed 2016·Granted Sep 10, 2019·0 cites·27 claims
Join the waitlist — get patent alerts
Get an alert when HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →